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ABSTRACT
Oral mucositis occurs in up to 75% of recipients of high-dose chemoradiotherapy conditioning regimens
used for allogeneic hematopoietic stem cell transplantation (HSCT). As a result of mucositis, narcotic
analgesia and total parenteral nutrition (TPN) are commonly required after HSCT. Methotrexate, an
antiproliferative graft-versus-host disease (GVHD) prophylaxis agent, impairs mucosal regeneration and
worsens and prolongs mucositis. We assessed the effect of substituting sirolimus for methotrexate as
GVHD prophylaxis on outcomes associated with mucositis. Two patient cohorts undergoing allogeneic
HLA-matched related donor peripheral blood stem cell transplantation with cyclophosphamide/total body
irradiation conditioning were prospectively analyzed for mucositis severity and retrospectively reviewed
for correlative outcomes. GVHD prophylaxis consisted of sirolimus/tacrolimus (ST) in the study group
and tacrolimus/methotrexate (TM) in the control group. Thirty patients received ST and 24 patients
received TM as GVHD prophylaxis between October 2000 and May 2003. Mild, moderate, and severe
mucositis was noted in 37%, 57%, and 7% of the ST group and 8%, 42%, and 50% of the TM group (P 
.0002). Less TPN was used in the ST group than the TM group (17% versus 43% of posttransplantation
hospital days; P  .02). The total number of narcotic days was lower in the ST group in comparison with
the TM group (median, 13.5 versus 17 days; P  .08). The time to first hospital discharge was shorter in
the ST group compared with the TM group (median, 18 versus 22 days; P  .07). The substitution of
sirolimus for methotrexate as GVHD prophylaxis is associated with a reduction in mucositis severity. As
a result, TPN and narcotic use are reduced, and hospitalization duration is shortened. Less toxic GVHD
prophylaxis regimens without methotrexate may have a significant effect on patient quality of life, patient
outcomes, and economic outcomes associated with allogeneic stem cell transplantation.
© 2005 American Society for Blood and Marrow Transplantation
KEY WORDS
Oral mucositis ● Sirolimus ● Stem cell transplantation
c
i
t
i
oNTRODUCTION
Mucositis is a frequent complication of high-dose
hemoradiotherapy regimens commonly used as con-
itioning therapy before allogeneic hematopoietic
tem cell transplantation (HSCT). Oral mucositis oc- H
B&MTurs as a result of chemotherapy- and radiotherapy-
nduced mucosal epithelial injury, submucosal endo-
helial injury, and connective tissue injury in an
mmunocompromised host. [1] Severe oral mucositis
ccurs in up to 75% of myeloablative allogeneic
SCT recipients, often occurs within the ﬁrst week
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3fter conditioning therapy, and usually resolves only
hen normal hematopoiesis resumes. [2]
Oral mucositis is a signiﬁcant problem for most
SCT recipients and has been reported to be the
ost debilitating side effect of transplantation. [3,4]
ucositis has immediate detrimental effects on pa-
ient quality of life by causing oral and oropharyngeal
ain and by impairing communication and swallow-
ng. As a result of pain related to mucositis, narcotic
nalgesia and parenteral nutrition are commonly re-
uired in the recovery period after HSCT. In addi-
ion, oral mucositis is associated with adverse eco-
omic and clinical outcomes after HSCT, including
n increased length of hospital stay and decreased
urvival at 100 days. [5] Although several attempts at
reventing, minimizing, and treating mucositis after
llogeneic stem cell transplantation have been made,
o single therapy has been shown to be effective in
andomized clinical trials, and the current standard
herapy for mucositis is supportive care alone. [6,7]
Although conditioning therapy is the most impor-
ant cause of mucositis after allogeneic HSCT, the
ontribution of methotrexate as graft-versus-host dis-
ase (GVHD) prophylaxis cannot be overlooked. As
n antiproliferative agent, methotrexate impairs mu-
osal regeneration after conditioning-related injury,
hereby prolonging and worsening oral mucositis.
he risk of mucositis is particularly increased among
ethotrexate recipients who carry the methylenetet-
ahydrofolate reductase 677 TT genotype, because of
mbalances in intracellular folate pools. [8]
At the Dana-Farber Cancer Institute, we have
erformed several clinical trials to assess the efﬁcacy
f sirolimus, a novel immunosuppressive agent, as
VHD prophylaxis when given in addition to or in
ieu of methotrexate. [9,10] Herein, we report a ret-
ospective cohort analysis comparing outcomes re-
ated to mucositis in patients who received a siroli-
us-based, methotrexate-free GVHD prophylaxis
egimen with outcomes in patients who received a
ethotrexate-containing regimen.
ETHODS
xperimental Design
This was a cohort analysis examining oral mucositis
utcomes of patients undergoing allogeneic peripheral
lood stem cell transplantation from HLA-matched,
elated donors for hematologic malignancies. Two
ohorts of patients were prospectively evaluated for
he oral mucositis outcomes of interest. Oral mucositis
as assessed prospectively at the time of transplanta-
ion, and the associated outcomes were assessed ret-
ospectively.
The experimental cohort consisted of 30 consec-
tive patients who underwent matched related donor o
84llogeneic peripheral blood stem cell transplantation
y using a novel GVHD prophylaxis regimen. Details
n this experimental protocol have been previously
ublished. [10] Brieﬂy, patients received myeloabla-
ive conditioning therapy with cyclophosphamide
1800 mg/m2/d for 2 days) and total body irradiation
14 Gy in 7 fractions) before peripheral blood stem
ell transplantation. GVHD prophylaxis consisted of
irolimus and tacrolimus (ST). No posttransplantation
ethotrexate was given.
The control population consisted of all other pa-
ients who underwent matched related donor periph-
ral blood stem cell transplantation at the Dana-Farber
ancer Institute with an identical conditioning regi-
en, but with the standard GVHD prophylaxis regi-
en of tacrolimus and methotrexate (TM; 15 mg/m2
ay 1 and 10 mg/m2 days 3, 6, and 11).
wenty four patients were identiﬁed as suitable con-
rols. No patient had had prior high-dose chemotherapy
ith stem cell support therapy. All subjects partici-
ated in institutional review board–approved proto-
ols allowing collection and analysis of data from
ransplantation.
ucositis Assessment
Patients were prospectively assessed thrice weekly
y trained and validated evaluators from the Oral
edicine Service of Brigham and Women’s Hospital
s part of routine clinical care. Oral evaluators were
ot blinded to GVHD prophylaxis assignment. The
everity of oral mucositis was assessed by using a
alidated scale in which the presence of mucosal ery-
hema or ulceration was determined for 8 predeﬁned
natomic locations in the oral cavity. [11] A mucositis
core of 0 connotes normal oral mucosa; 1 indicates
he presence of erythema only; 2 and 3 reﬂect the
resence of ulceration of 1 or 2 sites, respectively
slight to moderate mucositis); and 4 (3 ulcerative
ites) or 5 (3 sites of ulceration) is consistent with
evere mucositis.
Information on the use and duration of use of total
arenteral nutrition (TPN) and narcotics, as corre-
ates of oral mucositis, was collected by a retrospective
hart review. Narcotic use was obtained from elec-
ronic pharmacy dispensation records. Narcotics were
onverted to morphine equivalents by using published
arcotic conversion tables. [12]
tatistical Analysis
Descriptive statistical analyses were performed to
ompare demographic characteristics, including age, sex,
onor type, malignant disease, and disease status at the
ime of transplantation. Time to engraftment was mea-
ured by cumulative incidence. The Cochrane-Mantel-
aenszel statistic was used to compare the severity of
ral mucositis (mild, moderate, and severe) between
t
u
d
t
T
e
F
d
m
R
i
p
H
t
h
(
e
p
M
q
t
T
g
T
c
P
(
c
d
w
m
.
(
b
r
c
g
p
e
T
S
M
M
H
D
G
N
A
T
S
T
P
F
s
o
r
i
t
o
s
i
o
c
Mucositis after HSCT
Bhe 2 groups. A 2-sided Wilcoxon rank sum test was
sed for the comparison of duration of oral mucositis,
ays and doses of narcotics administered, time from
ransplantation to ﬁrst hospital discharge, and days of
PN use with and without adjustment for the differ-
nce in total hospital days between groups. A 2-sided
isher exact test was used to compare GVHD inci-
ence, TPN use, and the incidence of severe oral
ucositis.
ESULTS
The demographic and transplantation character-
stics of patients in this study are shown in Table 1. All
atients received peripheral blood stem cells from
LA-matched related donors. There were no statis-
ical differences between the 2 groups when age, sex,
ematologic malignancy, and the incidence of acute
grade II-IV) GVHD were examined. The ST group
ngrafted neutrophils (500/L) 1 day earlier in com-
arison to the TM group (14 versus 15 days; P  .04).
ucositis
Screening for mucositis occurred with equal fre-
uency for ST and TM patients (median, 5 versus 6.5
imes; P  .36). Peak mucositis scores are shown in
able 2. Oral mucositis was less severe in the ST
roup than in the TM group (P  .0002; Figure 1).
he incidence of severe, ulcerating (grade 4/5) mu-
ositis was lower in the ST group (50% versus 6.7%;
 .001). The median number of days with mucositis
able 1. Baseline Characteristics
Variable Sirolimus/T
ample size 30
edian age, y (range) 42 (19
ale sex 16 (53
ematologic malignancy
AML 10 (33
CML 7 (23
NHL 7 (23
MDS 5 (17
ALL 1 (3%
ays to neutrophil engraftment (range) 14 (11
rade II-IV acute GVHD 3 (10
o signiﬁcant differences in baseline characteristics were observed
engraftment.
ML indicates acute myelogenous leukemia; CML, chronic myelog
syndrome; ALL, acute lymphatic leukemia.
able 2. Incidence of Oral Mucositis by Severity
Variable
Peak Mucositis Score
0/1 2/3 4/5
irolimus/tacrolimus 11 (37%) 17 (57%) 2 (7%)
acrolimus/methotrexate 2 (8%) 10 (42%) 12 (50%) .0002. c
B&MT2) among the entire ST group was reduced when
ompared with the TM group (median, 4.5 versus 9.5
ays; P  .008; Figure 1). However, among patients
ith mucositis, the median number of days with a
ucositis score 2 (median, 8 versus 12 days; P 
19), 3 (median, 5 versus 9 days; P  .11), and 4
median, 10 versus 8 days; P  1.00) was similar
etween the ST and TM groups. There was no cor-
elation between time to engraftment and peak mu-
ositis score. Four individuals in the TM group en-
rafted on or after day 21. These 4 individuals all had
eak mucositis scores 2, and 2 individuals experi-
nced grade 4 or 5 mucositis.
us Tacrolimus/Methotrexate P Value
24
43 (24-58) .46
11 (46%) .78
9 (38%)
3 (13%)
3 (13%)
7 (29%)
2 (8%) .52
15 (11-25) .04
6 (25%) .16
en treatment groups, with the exception of the time to neutrophil
leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic
igure 1. Mucositis incidence and duration. A, Peak mucositis
cores were signiﬁcantly lower in the ST group. B, Boxplot dem-
nstrating differences in mucositis duration. The limits of the box
epresent the 25th and 75th percentiles for the group, the solid line
n the center of the box represents the median for the group, and the
ails arising out of the box represents the range that includes 95% of
bserved values. Duration of mucositis 2 was also signiﬁcantly
horter. A mucositis score of 0 connotes normal oral mucosa; 1
ndicates the presence of erythema only; 2 and 3 reﬂect the presence
f ulceration of 1 or 2 sites, respectively (slight to moderate mu-
ositis); and 4 (3 ulcerative sites) or 5 (3 sites of ulceration) isacrolim
-54)
%)
%)
%)
%)
%)
)
-17)
%)
betwe
enousonsistent with severe mucositis.
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3arcotic Use
The total number of hospital days when narcotics
ere used as pain control was lower in the ST group
median, 13.5 versus 17 days; P  .08; Figure 2). The
otal dose of narcotics administered is expressed as in-
ravenous milligrams of morphine equivalents (MME).
atients in the ST arm received an average of 880
ME, in comparison to 1225 MME in the control
rm (Figure 2). Similarly, patients in the ST group
sed fewer MME per hospital day than the TM arm
median, 41.2 versus 61.7 MME per day; Figure 2) and
ewer MME per narcotic day (median, 61.9 versus
5.2 MME per narcotic day; Figure 2). None of these
esults achieved statistical signiﬁcance.
otal Parenteral Nutrition
The median number of days of TPN use in the ST
rm was signiﬁcantly lower than in the TM group
2 versus 14 days; P  .005; Figure 3) and was shorter
ven when controlling for the total number of post-
ransplantation hospital days (17% versus 43% of
osttransplantation hospital days; P  .02). A smaller
roportion of patients in the ST group required any
PN (50% versus 75%; P  .06), and among the
sers of TPN, the duration of TPN was signiﬁcantly
horter (13 versus 17.5 days; P  .03).
ength of Hospital Stay
Patients who received ST had a shorter length of
ospitalization from the time of transplantation when
ompared with the TM group (median length of stay,
8 versus 22 days; P  .07; Figure 4).
ISCUSSION
In this retrospective cohort analysis, we have dem-
nstrated that the use of a sirolimus-based, non–metho-
igure 2.Narcotic use. Patients in the ST group received narcotics
n fewer days after transplantation (P  .08). There was a trend to
ecreased total milligrams of morphine equivalents (MME) used
fter transplantation. When standardized to posttransplantation
ays or posttransplantation days when any narcotic was adminis-
ered, the trend to fewer MME remained. NS indicates not signif-
cant. w
86rexate-containing GVHD prophylaxis regimen is asso-
iated with a decrease in the incidence and severity of
ral mucositis after HLA-matched related donor periph-
ral blood stem cell transplantation. In addition, mucosi-
is-related outcomes, such as TPN use, narcotic use, and
ospitalization duration, are also improved when a non-
ethotrexate GVHD prophylaxis regimen is used. To
ate, 1 other trial has demonstrated a decrease in mu-
ositis and mucositis-related outcomes when methotrex-
te was replaced in the GVHD prophylaxis strategy. [13]
nother GVHD prophylaxis strategy used to diminish
ucositis is reduced-dose methotrexate; however, mu-
ositis outcomes with this approach have not been for-
ally evaluated.
Strategies used to prevent or reduce oral mucositis
fter allogeneic stem cell transplantation have included
trict oral hygiene, [14] glutamine supplementation,
15,16] topical and systemic hematopoietic growth fac-
igure 3. TPN use and duration of use. A, Less TPN was used in
he ST group (P  .08). B, The duration of TPN use was signiﬁ-
antly shorter in the ST group (P  .005).
igure 4. Duration of hospitalization: the hospitalization duration
as 4 days shorter from the time of transplantation in the ST group.
t
t
t
a
h
i
b
d
f
t
d
t
3
a
4
[
i
t
c
e
s
h
t
c
n
e
e
s
i
o
l
t
p
a
p
r
s
t
p
b
u
d
c
p
f
t
i
w
b
l
o
v
a
o
t
o
m
O
t
m
w
c
t
h
m
m
s
G
p
t
r
n
o
e
c
b
b
t
a
p
c
m
t
i
a
t
i
m
o
l
a
p
m
c
t
t
A
0
a
I
t
C
R
Mucositis after HSCT
Bors, [17-20] interleukin 11, [21,22] and bacterial decon-
amination of the oral cavity. [23] Although some of
hese strategies yielded promising results, none is widely
ccepted as standard therapy. Several newer agents may
ave a potential role in the prevention of oral mucositis,
ncluding the protegrin-1-analog-iseganan [24] and ﬁ-
roblast growth factor 20, [25] although the clinical
evelopment of iseganan has now been abandoned. Pali-
ermin, a keratinocyte growth factor analog, has shown
he most promise. In a randomized phase III study con-
ucted in patients undergoing autologous transplanta-
ion, the incidence of World Health Organization grade
/4 mucositis was reduced from 98% to 63% (P .001),
nd the incidence of World Health Organization grade
mucositis was reduced from 62% to 20% (P  .001).
26] In addition, palifermin use was associated with an
mproved quality of life of patients undergoing stem cell
ransplantation [27] and with favorable economic out-
omes. [28]
In our observational study, we observed clinical ben-
ﬁts similar to those seen in the palifermin trial, with
imilar reductions in narcotic use and TPN use. The
ospitalization duration was shortened by 4 days when
he nonmethotrexate and methotrexate cohorts were
ompared. Although this result was not statistically sig-
iﬁcant, likely because of the small sample size, a differ-
nce of 4 days is clinically relevant. Much of this differ-
nce could be attributable to the more rapid engraftment
een in the nonmethotrexate cohort; however, the tim-
ng of discharge in relation to engraftment is often based
n the reinstitution of normal oral intake, which is re-
ated in part to oral mucositis. With hospitalization costs
hat exceed $150 000 for traditional, non–T cell–de-
leted transplantation, [29] this reduction in hospital stay
lone may amount to signiﬁcant cost savings for trans-
lantation programs and insurers. However, when the
eductions in TPN and narcotic use are added, the cost
avings associated with prevention of ulcerative mucosi-
is may be associated with a savings of more than $42 000
er hospital stay. [5] These cost savings, however, may
e offset by the increased costs associated with sirolimus
se, which in this study was administered for at least 100
ays after transplantation. The true cost-beneﬁt out-
omes of this strategy, incorporating the costs of pro-
hylaxis and therapy of GVHD, are the subject of a
ormal cost-efﬁcacy analysis.
It has been demonstrated that chemotherapy pa-
ients who do not experience mucositis have a decreased
ncidence of mood disturbance compared with those
ho experience mucositis. [30] Although mood distur-
ance is an important measure of quality of life, it is
ikely to be only 1 of many contributing factors. Quality
f life in the immediate posttransplantation period is
ery difﬁcult to ascertain, and alterations in quality of life
re difﬁcult to ascribe to single-system problems because
f the inherent multifactorial nature of posttransplanta-
ion complications. Therefore, when trying to consider
B&MTral mucositis outcomes alone, it is difﬁcult to deter-
ine what are the clinically important end points.
ne attempt to address this issue has been the use of
he European Organization for Research and Treat-
ent of Cancer Quality of Life Questionnaire C30,
ith the oral addendum module. [31] The oral mu-
ositis patient provider advisory board has suggested
hat reductions in oral pain, opioid analgesic use, and
ospitalization duration are among the important
arkers. [32] Because we have demonstrated improve-
ents in all 3 of these domains, it is likely that the
ubstitution of sirolimus for methotrexate in the
VHD prophylaxis regimen is associated with an im-
rovement in quality of life in the immediate post-
ransplantation time period.
It is likely that very little bias inﬂuenced the analyses
eported here. Although the trained oral observers were
ot blinded to GVHD prophylaxis, the nature of this
bservational study was unknown to them, and their
xaminations were part of routine clinical care. Similarly,
linicians caring for the patients in this study could have
ased decisions to implement parenteral nutrition biased
y GVHD prophylaxis. However, the recommendations
o institute parenteral nutrition were generally made by
nutritionist specializing in the care transplantation
atients who was unaware of this observational study.
In summary, when compared with methotrexate-
ontaining GVHD prophylaxis regimens after HLA-
atched related donor peripheral blood stem cell
ransplantation, the use of a sirolimus-based regimen
s associated with improved mucositis and mucositis-
ssociated outcomes. Given only a 1-day difference in
he time to engraftment between cohorts examined, it
s likely that the methotrexate contributed directly to
ucositis in this study. GVHD strategies that reduce
r eliminate methotrexate from the GVHD prophy-
axis regimen should be pursued to improve mucositis
nd mucositis-related outcomes after allogeneic trans-
lantation, as long as GVHD control is not compro-
ised. As such, a randomized clinical comparing the
ombinations of ST with TM will be performed. Al-
hough GVHD is the primary focus of this trial, mucosi-
is outcomes will be important secondary end points.
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